title: DisABLing kidney cancers caused by fumarate hydratase mutations.
abstract: Reprogramming of cellular metabolism by oncogenic mutations probably creates specific vulnerabilities that could be exploited therapeutically. In this issue of Cancer Cell, Sourbier and colleagues show that kidney cancers lacking fumarate hydratase display increased sensitivity to agents that interfere with their ability to cope with reactive oxygen species.
authors.affiliation: Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA. Electronic address: william_kaelin@dfci.harvard.edu.
authors.forename: William G
authors.initials: WG
authors.lastname: Kaelin
mesh_terms: D000818:Animals; D005649:Fumarate Hydratase / Q000172:deficiency*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D018384:Oxidative Stress / Q000187:drug effects*; D010880:Piperidines / Q000494:pharmacology*; D016315:Proto-Oncogene Proteins c-abl / Q000378:metabolism*; D011799:Quinazolines / Q000494:pharmacology*
chemical_list: D010880:Piperidines; D011799:Quinazolines; D016315:Proto-Oncogene Proteins c-abl; D005649:Fumarate Hydratase; C452423:vandetanib